Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colitis Suppositories
- Development stage
- Phase 2
- Lead developer
- Shandong Kangzhonghong Medical Technology Development
- Administration
- Rectal
01
Overview
Colitis Suppositories is a pharmaceutical drug in suppository form, developed by Shandong Kangzhonghong Medical Technology Development Co. Ltd. It is currently undergoing a preliminary exploratory phase IIa clinical trial for the treatment of mild-to-moderate active ulcerative colitis. The drug is administered rectally. While the specific mechanism of action is not detailed, it is being compared to Mesalazine Suppositories, which are known for their anti-inflammatory effects in the colon.
Beyond the preview
Go deeper on Colitis Suppositories.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Colitis Suppositories.